Dimensional Fund Advisors LP Has $61.91 Million Position in Hims & Hers Health, Inc. (NYSE:HIMS)

Dimensional Fund Advisors LP decreased its holdings in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 11.8% in the 4th quarter, HoldingsChannel reports. The firm owned 2,560,103 shares of the company’s stock after selling 342,131 shares during the period. Dimensional Fund Advisors LP’s holdings in Hims & Hers Health were worth $61,910,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Barclays PLC raised its position in shares of Hims & Hers Health by 9.7% in the third quarter. Barclays PLC now owns 308,363 shares of the company’s stock valued at $5,680,000 after purchasing an additional 27,231 shares during the period. Principal Financial Group Inc. raised its holdings in Hims & Hers Health by 102.0% in the 3rd quarter. Principal Financial Group Inc. now owns 290,414 shares of the company’s stock valued at $5,349,000 after acquiring an additional 146,621 shares during the period. GAMMA Investing LLC lifted its position in Hims & Hers Health by 2,173.7% during the fourth quarter. GAMMA Investing LLC now owns 2,251 shares of the company’s stock worth $54,000 after acquiring an additional 2,152 shares during the last quarter. Cadent Capital Advisors LLC boosted its holdings in shares of Hims & Hers Health by 1.5% during the fourth quarter. Cadent Capital Advisors LLC now owns 72,160 shares of the company’s stock worth $1,745,000 after acquiring an additional 1,060 shares during the period. Finally, CHURCHILL MANAGEMENT Corp acquired a new position in shares of Hims & Hers Health in the fourth quarter valued at approximately $445,000. 63.52% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

HIMS has been the subject of several recent research reports. TD Cowen downgraded Hims & Hers Health from a “buy” rating to a “hold” rating and reduced their price target for the company from $44.00 to $30.00 in a research note on Tuesday. Truist Financial decreased their price target on shares of Hims & Hers Health from $39.00 to $33.00 and set a “hold” rating on the stock in a research note on Thursday, April 10th. BTIG Research began coverage on shares of Hims & Hers Health in a research note on Tuesday, January 7th. They issued a “buy” rating and a $35.00 price objective for the company. Needham & Company LLC increased their target price on shares of Hims & Hers Health from $31.00 to $61.00 and gave the stock a “buy” rating in a research report on Tuesday, February 25th. Finally, Bank of America lifted their price target on shares of Hims & Hers Health from $22.00 to $26.00 and gave the company an “underperform” rating in a research report on Tuesday. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat, Hims & Hers Health currently has a consensus rating of “Hold” and an average price target of $36.92.

Hims & Hers Health Stock Performance

Shares of HIMS opened at $36.39 on Friday. Hims & Hers Health, Inc. has a 52-week low of $11.20 and a 52-week high of $72.98. The firm has a market cap of $8.09 billion, a price-to-earnings ratio of 82.72 and a beta of 1.65. The business’s fifty day moving average is $32.19 and its 200-day moving average is $31.30.

Hims & Hers Health (NYSE:HIMS) last released its earnings results on Monday, February 24th. The company reported $0.11 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.09 by $0.02. The firm had revenue of $481.14 million for the quarter, compared to analysts’ expectations of $494.56 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. As a group, research analysts forecast that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Insider Activity at Hims & Hers Health

In other news, COO Melissa Baird sold 33,333 shares of the company’s stock in a transaction that occurred on Monday, April 21st. The stock was sold at an average price of $25.78, for a total value of $859,324.74. Following the completion of the transaction, the chief operating officer now owns 805,083 shares of the company’s stock, valued at $20,755,039.74. This represents a 3.98 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Andrew Dudum sold 128,127 shares of Hims & Hers Health stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $58.27, for a total transaction of $7,465,960.29. Following the sale, the chief executive officer now owns 97,687 shares in the company, valued at approximately $5,692,221.49. This represents a 56.74 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 666,234 shares of company stock valued at $26,387,645 in the last quarter. Insiders own 17.71% of the company’s stock.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.